Clinical trial
Safety of a New Type of Treatment Called Gene Transfer for the Treatment of…
NCT00076557 · Avigen, Industry · Terminated
Key facts
| NCT number | NCT00076557 |
|---|---|
| Title | Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B |
| Official title | A Phase I Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using Adeno-Associated Viral Vector to Deliver the Gene for Human Factor IX Into the Liver |
| Lead sponsor | Avigen, Industry |
| Collaborators | Stanford University Children's Hospital of Philadelphia The Hemophilia Center of Western Pennsylvania University of Washington The University of Texas Health Science Center, Houston University of… |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hemophilia B |
| Intervention type | Genetic |
| Interventions | Adeno-Associated Viral with Human Factor IX |
| Enrollment | 15 |
| Start date | Jan 1, 2004 |
| First posted | Jan 28, 2004 |
| Last update posted | Apr 4, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: